Q1 FY27 Results: Revenue declines 36% YoY, PAT at Rs 13.15 lakh

Revenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹25.48

prior close

₹24.24

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-2.4% vs market

Commodity Chemicals peers, median of 56sector-0.4%-2.0% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.0 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4+0.0-2.4-0.4-2.0

Next day

-4.2-0.0-4.2-0.3-4.0

-3.7-0.2-3.5-1.0-2.7

-7.7+0.2-7.8-2.0-5.7

-6.8+0.3-7.1-2.0-4.8

-7.2+0.4-7.6-1.1-6.1

-4.3+0.9-5.2-2.1-2.2

15d

-1.9+1.6-3.5-0.9-1.0

-3.0+2.0-5.0+1.1-4.1

-7.7+0.6-8.2+0.7-8.4

—————

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 56Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emmessar Biotech & Nutrition reported Q1 FY27 (ended 30 June 2026) unaudited results. Revenue from operations fell to Rs 5.93 lakh from Rs 9.28 lakh YoY, a 36 percent decline. Total income stood at Rs 59.85 lakh vs Rs 62.70 lakh. Net profit declined to Rs 13.15 lakh from Rs 17.12 lakh YoY. EPS was Rs 0.26 vs Rs 0.34. Auditor V. Nagarajan and Co. issued an unqualified limited review report. 34th AGM scheduled for 29 September 2026.

Likely market impact

Weak core healthcare revenue continues, but lease rental income props up profits. Watch for recovery in the operating segment.